![References in Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project - The Lancet Oncology References in Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e9f0b5cb-9cc5-42db-a8cd-42ce83de0d6d/gr1.jpg)
References in Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project - The Lancet Oncology
![Aaron Boster MD on Twitter: "Click to learn how Tysabri (Natalizumab) works in #MS: https://t.co/TUYQqJTzQo #MultipleSclerosis #Tysabri https://t.co/WC7xvLO3EK" / Twitter Aaron Boster MD on Twitter: "Click to learn how Tysabri (Natalizumab) works in #MS: https://t.co/TUYQqJTzQo #MultipleSclerosis #Tysabri https://t.co/WC7xvLO3EK" / Twitter](https://pbs.twimg.com/media/C3NZaIuWYAEkCIN.jpg)
Aaron Boster MD on Twitter: "Click to learn how Tysabri (Natalizumab) works in #MS: https://t.co/TUYQqJTzQo #MultipleSclerosis #Tysabri https://t.co/WC7xvLO3EK" / Twitter
![Frontiers | Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases | Cell and Developmental Biology Frontiers | Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases | Cell and Developmental Biology](https://www.frontiersin.org/files/Articles/612830/fcell-09-612830-HTML/image_m/fcell-09-612830-g001.jpg)
Frontiers | Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases | Cell and Developmental Biology
![VLA‐4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow - White - 2016 - British Journal of Haematology - Wiley Online Library VLA‐4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow - White - 2016 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/7097d3fa-46ad-4fc0-ba63-a43ade0c5d95/bjh14158-fig-0006-m.jpg)
VLA‐4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow - White - 2016 - British Journal of Haematology - Wiley Online Library
![Natalizumab and glatiramer acetate mechanism of action. A. Natalizumab... | Download Scientific Diagram Natalizumab and glatiramer acetate mechanism of action. A. Natalizumab... | Download Scientific Diagram](https://www.researchgate.net/profile/Pablo-Villoslada/publication/23470882/figure/fig2/AS:667224238997513@1536090063751/Natalizumab-and-glatiramer-acetate-mechanism-of-action-A-Natalizumab-blocks-the.png)
Natalizumab and glatiramer acetate mechanism of action. A. Natalizumab... | Download Scientific Diagram
![Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR) - Sabol - 2017 - Cancer Medicine - Wiley Online Library Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR) - Sabol - 2017 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/2fab7883-f946-4f8c-b302-b0c33b58d7cc/cam41098-fig-0002-m.jpg)
Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR) - Sabol - 2017 - Cancer Medicine - Wiley Online Library
![Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring - The Lancet Neurology Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring - The Lancet Neurology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2000992662/2003668235/gr1.jpg)